You are here
Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration.
Wednesday,2015-03-04 14:22 America/Los_Angeles — zdrager
| Title | Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration. |
| Publication Type | Journal Article |
| Year of Publication | 2016 |
| Authors | Willeit, P, Thompson, SG, Agewall, S, Bergström, G, Bickel, H, Catapano, AL, Chien, K-L, de Groot, E, Empana, J-P, Etgen, T, Franco, OH, Iglseder, B, Johnsen, SH, Kavousi, M, Lind, L, Liu, J, Mathiesen, EB, Norata, GD, Olsen, MH, Papagianni, A, Poppert, H, Price, JF, Sacco, RL, Yanez, DN, Zhao, D, Schminke, U, Bülbül, A, Polak, JF, Sitzer, M, Hofman, A, Grigore, L, Dörr, M, Su, T-C, Ducimetiere, P, Xie, W, Ronkainen, K, Kiechl, S, Rundek, T, Robertson, C, Fagerberg, B, Bokemark, L, Steinmetz, H, Ikram, AM, Völzke, H, Lin, H-J, Plichart, M, Tuomainen, T-P, Desvarieux, M, McLachlan, S, Schmidt, C, Kauhanen, J, Willeit, J, Lorenz, MW, Sander, D |
| Corporate/Institutional Authors | PROG-IMT Study Group, |
| Journal | Eur J Prev Cardiol |
| Volume | 23 |
| Issue | 2 |
| Pagination | 194-205 |
| Date Published | 2016 Jan |
| ISSN | 2047-4881 |
| Abstract | <p><b>BACKGROUND: </b>Large-scale epidemiological evidence on the role of inflammation in early atherosclerosis, assessed by carotid ultrasound, is lacking. We aimed to quantify cross-sectional and longitudinal associations of inflammatory markers with common-carotid-artery intima-media thickness (CCA-IMT) in the general population.</p><p><b>METHODS: </b>Information on high-sensitivity C-reactive protein, fibrinogen, leucocyte count and CCA-IMT was available in 20 prospective cohort studies of the PROG-IMT collaboration involving 49,097 participants free of pre-existing cardiovascular disease. Estimates of associations were calculated within each study and then combined using random-effects meta-analyses.</p><p><b>RESULTS: </b>Mean baseline CCA-IMT amounted to 0.74 mm (SD = 0.18) and mean CCA-IMT progression over a mean of 3.9 years to 0.011 mm/year (SD = 0.039). Cross-sectional analyses showed positive linear associations between inflammatory markers and baseline CCA-IMT. After adjustment for traditional cardiovascular risk factors, mean differences in baseline CCA-IMT per one-SD higher inflammatory marker were: 0.0082 mm for high-sensitivity C-reactive protein (p < 0.001); 0.0072 mm for fibrinogen (p < 0.001); and 0.0025 mm for leucocyte count (p = 0.033). 'Inflammatory load', defined as the number of elevated inflammatory markers (i.e. in upper two quintiles), showed a positive linear association with baseline CCA-IMT (p < 0.001). Longitudinal associations of baseline inflammatory markers and changes therein with CCA-IMT progression were null or at most weak. Participants with the highest 'inflammatory load' had a greater CCA-IMT progression (p = 0.015).</p><p><b>CONCLUSION: </b>Inflammation was independently associated with CCA-IMT cross-sectionally. The lack of clear associations with CCA-IMT progression may be explained by imprecision in its assessment within a limited time period. Our findings for 'inflammatory load' suggest important combined effects of the three inflammatory markers on early atherosclerosis.</p> |
| DOI | 10.1177/2047487314560664 |
| Alternate Journal | Eur J Prev Cardiol |
| PubMed ID | 25416041 |
| PubMed Central ID | PMC4544641 |
| Grant List | AG023629 / AG / NIA NIH HHS / United States HHSN268200800007C / HL / NHLBI NIH HHS / United States HHSN268200800007C / / PHS HHS / United States HHSN268201200036C / HL / NHLBI NIH HHS / United States HHSN268201200036C / / PHS HHS / United States HL080295 / HL / NHLBI NIH HHS / United States MR/L003120/1 / / Medical Research Council / United Kingdom N01 HC55222 / HC / NHLBI NIH HHS / United States N01HC35129 / HC / NHLBI NIH HHS / United States N01HC45133 / HC / NHLBI NIH HHS / United States N01HC55222 / HL / NHLBI NIH HHS / United States N01HC85079 / HC / NHLBI NIH HHS / United States N01HC85079 / HL / NHLBI NIH HHS / United States N01HC85080 / HC / NHLBI NIH HHS / United States N01HC85080 / HL / NHLBI NIH HHS / United States N01HC85081 / HC / NHLBI NIH HHS / United States N01HC85081 / HL / NHLBI NIH HHS / United States N01HC85082 / HC / NHLBI NIH HHS / United States N01HC85082 / HL / NHLBI NIH HHS / United States N01HC85083 / HC / NHLBI NIH HHS / United States N01HC85083 / HL / NHLBI NIH HHS / United States N01HC85084 / HC / NHLBI NIH HHS / United States N01HC85085 / HC / NHLBI NIH HHS / United States N01HC85086 / HC / NHLBI NIH HHS / United States N01HC85086 / HL / NHLBI NIH HHS / United States R01 AG023629 / AG / NIA NIH HHS / United States R37 NS 029993 / NS / NINDS NIH HHS / United States RG/08/014/24067 / / British Heart Foundation / United Kingdom U01 HL080295 / HL / NHLBI NIH HHS / United States |